StockGuru Blog: End of Year Report New Ticker: OTCBB: IMRP Immune Response Corp.
IMRP.OB - The Immune Response Corporation StockGuru Profile IMRP The Immune Response Corporation has issued an end of year report. The Immune Response Corporation’s product pipeline has two clinical stage therapeutics in phase 2 development, NeuroVax for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by Spelman Research’s Stelian Mitu, an experienced investment research analyst, who received his CFA charter in 2003 and MBA degree in 1997. In the Spelman report, Mitu writes, “The drug candidates, IR103 (HIV) and NeuroVax (MS), are based on innovative technologies that do not have analogues on the market…. If successful, IMNR’s…